Literature DB >> 10951266

Matrix metalloproteinases in human melanoma.

U B Hofmann1, J R Westphal, G N Van Muijen, D J Ruiter.   

Abstract

Cutaneous melanoma is a highly invasive and metastatic tumor. Degradation of basement membranes and extracellular matrix is an essential step in melanoma cell migration, invasion, and metastasis formation. Matrix metalloproteinases and their tissue inhibitors play a crucial role in these complex multistep processes. Melanoma cells may express a number of matrix metalloproteinase family members (MMP-1, MMP-2, MMP-9, MMP-13, and MT1-MMP) as well as their tissue inhibitors (TIMP-1, TIMP-2, and TIMP-3). Numerous studies have examined matrix metalloproteinases, their tissue inhibitors, and the molecules that regulate their expression and/or activation in melanoma cell lines in vitro and in vivo, and in human melanocytic lesions. Recent results have indicated that adhesion molecules such as CD44 and integrin alphavbeta3 are involved in positioning activated matrix metalloproteinase molecules on the cell surface of invasive tumor cells. In this review we evaluate these novel aspects of the role of matrix metalloproteinases and their tissue inhibitors in melanoma progression. We conclude that the balance between levels of activated matrix metalloproteinases and expression levels of their tissue inhibitors, and the coexpression of activated matrix metalloproteinases and adhesion molecules are important factors in determining melanoma cell invasion, tumor growth, and metastasis formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951266     DOI: 10.1046/j.1523-1747.2000.00068.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  104 in total

1.  Using fluorogenic peptide substrates to assay matrix metalloproteinases.

Authors:  G B Fields
Journal:  Methods Mol Biol       Date:  2001

2.  MMP2 expression is a prognostic marker for primary melanoma patients.

Authors:  Anand Rotte; Magdalena Martinka; Gang Li
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

3.  Variability in melanoma metalloproteinase expression profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  J Biomol Tech       Date:  2010-12

4.  Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2.

Authors:  Emmanuelle Godefroy; Nina Bhardwaj
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

5.  Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe.

Authors:  Walter J Akers; Baogang Xu; Hyeran Lee; Gail P Sudlow; Gregg B Fields; Samuel Achilefu; W Barry Edwards
Journal:  Bioconjug Chem       Date:  2012-02-29       Impact factor: 4.774

Review 6.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

7.  Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion.

Authors:  Rubén A Bartolomé; Isabel Molina-Ortiz; Rafael Samaniego; Paloma Sánchez-Mateos; Xosé R Bustelo; Joaquin Teixidó
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

8.  Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen.

Authors:  Jennifer M Roth; Maresa Caunt; Alexandra Cretu; Abebe Akalu; Desiree Policarpio; Xiaolu Li; Paul Gagne; Silvia Formenti; Peter C Brooks
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

9.  Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Rian Disci; Sidika Kurul; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

10.  Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models.

Authors:  Tatsuhiko Kasaoka; Hiroko Nishiyama; Mikiko Okada; Motowo Nakajima
Journal:  Clin Exp Metastasis       Date:  2008-07-31       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.